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Abstract: Germline variants in DNA repair genes are associated with aggressive prostate cancer (PrCa).
The aim of this study was to characterize germline variants in DNA repair genes associated with lethal
PrCa in Finnish and Swedish populations. Whole-exome sequencing was performed for 122 lethal and
60 unselected PrCa cases. Among the lethal cases, a total of 16 potentially damaging protein-truncating
variants in DNA repair genes were identified in 15 men (12.3%). Mutations were found in six genes
with CHEK2 (4.1%) and ATM (3.3%) being most frequently mutated. Overall, the carrier rate of
truncating variants in DNA repair genes among men with lethal PrCa significantly exceeded the
carrier rate of 0% in 60 unselected PrCa cases (p = 0.030), and the prevalence of 1.6% (p < 0.001) and
5.4% (p = 0.040) in Swedish and Finnish population controls from the Exome Aggregation Consortium.
No significant dierence in carrier rate of potentially damaging nonsynonymous single nucleotide
variants between lethal and unselected PrCa cases was observed (p = 0.123). We confirm that DNA
repair genes are strongly associated with lethal PrCa in Sweden and Finland and highlight the
importance of population-specific assessment of variants contributing to PrCa aggressiveness.
Keywords: prostate cancer; DNA repair genes; lethal cancer
1. Introduction
Prostate cancer (PrCa), the most common male cancer worldwide, has a wide spectrum of clinical
behavior that ranges from decades of indolence to rapid metastatic progression and lethality [1]. PrCa
is also among the most heritable human cancers, with 57% of the interindividual variation in risk
attributed to genetic factors [2]. Genome-wide association studies (GWAS) have thus far confirmed
~170 susceptibility loci that account for over 30% of the familial relative risk [3]. However, the risk
variants identified using case-control designs show little or no ability to discriminate between indolent
and fatal forms of this disease [4]. Therefore, studies contrasting patients with more and less aggressive
disease and those exploring associations with disease progression and prognosis should be more
eective at detecting genetic risk factors for aggressive PrCa with prognostic potential.
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Inherited and acquired defects in DNA repair genes are a common hallmark of cancer and, to date,
numerous inherited DNA repair gene mutations that increase cancer risk has been identified [5].
In particular, mutations in BRCA1 and BRCA2 genes, both associated with several DNA repair
pathways, confer a strikingly increased risk of breast and ovarian cancer [6]. In addition, it is now
recognized that the downregulation of DNA repair response is necessary for tumor progression into a
more aggressive phenotype [5]. Accumulating evidence suggests that pathogenic germline variants in
known cancer-predisposing genes such as BRCA2 can increase the risk of developing PrCa, especially
the more aggressive form of the disease [7]. Likewise, several other genes that were initially implicated
as high-risk genes in cancers other than PrCa, such as CHEK2 and BRIP1, have subsequently been
shown to increase the risk of PrCa as well [8–10]. Recent studies have reported a high carrier rate of
inherited DNA repair gene mutations among men with metastatic PrCa (11.8%), significantly exceeding
the prevalence (4.6%) among men with localized PrCa [11].
In this study, we evaluated germline variants of DNA repair genes in men who died of PrCa.
The aim of our study was to identify and investigate the frequency of pathogenic germline variants in
men with the lethal form of the disease.
2. Materials and Methods
2.1. Study Subjects
Genomic DNA from a total of 122 lethal PrCa patients was collected from an ongoing collection of
Finnish PrCa patients (TAMPERE, n = 47) and the Swedish Cancer of Prostate in Sweden (CAPS, n = 75)
study. To create an extremely aggressive phenotype, the inclusion criterion for lethal PrCa cases was that
the patient should have died due to PrCa before the age of 65. All of the Finnish patients were recruited
in the Pirkanmaa Hospital District as part of a hereditary PrCa family collection or through collection
of sporadic cases treated at the regional hospital [12]. The Swedish CAPS study is a population-based
case-control study that enrolled participants between 2001 and 2003 [13]. An additional 70 PrCa
patients from the TAMPERE population, not selected for disease aggressiveness or young age at death
(hereby denoted unselected cases), with whole-exome sequencing data available were also included
to contrast against the lethal cases. Clinical information, such as clinical stage, pathologic grade,
nodal or distant metastases, and diagnostic serum levels of PSA and vital status, including cause
of death, was obtained through medical records and national cancer registries. All samples were
collected with written and signed informed consent. The project was approved by the research ethics
committee at Pirkanmaa Hospital District (R03203), the Finnish National Supervisory Authority of
Welfare and Health (5569/32/300/05) and by the ethics committees at the Karolinska Institutet (04-449/4
and 06-381/32).
2.2. Sample Preparation, Sequencing and Genotyping
Genomic DNA was extracted from whole blood by standard methods. For the 122 lethal cases,
exome capture was performed using Agilent SureSelect Human All Exon 50 M kit (Agilent Technologies,
Inc., Santa Clara, CA, USA) according to standard protocol and sequenced at the Science for Life
laboratory (Stockholm, Sweden). Of the 70 unselected cases 25 samples were sequenced by BGI Tech
Solutions (Hong Kong, China) with exome capture performed by the SureSelect Human All Exon 50 M
kit while the remaining 45 unselected cases were sequenced at Mayo Clinic, Rochester, MN, USA with
exome capture performed using Agilent SureSelect Human All Exon 50Mb or V4+UTR kits. At each
site samples were sequenced using the Illumina Hiseq (Illumina, Inc, San Diego, CA, USA).
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2.3. Sample Quality Control and Variant Calling
The reads were aligned against the hg19 genome build retrieved from UCSC using BWA [14].
BEDtools [15] was used to calculate the genome-wide coverage for each sample where samples with less
than 30% of bases covered by at least 20 reads were excluded. The PCR duplicates were marked using
PICARD [16], and the base score recalibration was performed using GATK [17]. Subsequently, GATK
was used to call the variants and genotypes following the GATK best practices protocol for germline
exome-sequencing data [18,19]. The candidate false-positive variants were initially filtered using the
variant quality score recalibration procedure using the tranche threshold 99.0. Furthermore, variants
having an allele fraction of less than 0.3 or a coverage of less than 12 were filtered out. Finally, variants
with a readPosRankSum less than or equal to  1.7 were discarded. The variants were annotated using
ANNOVAR [20].
2.4. Variant Prioritization
Variants found in 175 DNA repair genes [21–23] were selected for further analysis. To prioritize
variants for validation, we utilized a similar approach to that introduced by Mijuskovic and
coworkers [7]. The intergenic and common (minor allele frequency > 0.01) variants were filtered out.
The remaining rare variants were classified into two categories: potentially damaging and neutral.
The potentially damaging variants were further classified into two categories (Tier 1 and Tier 2) based
on their impact. The classification was performed utilizing a database of reported associations of
variants to clinical phenotypes (ClinVar) provided by ANNOVAR and two tools for pathogenicity
prediction, CADD [24] and REVEL [25], of which the latter is specifically designed for discovery of
rare deleterious variants. Moreover, the known protein domains from the UniProt [26] database were
utilized to assess the pathogenicity of protein truncating variants.
Those variants that are reported as likely benign or benign in ClinVar were classified as neutral.
Protein truncating variants (stopgain, frameshift indels or splicing site altering variants) were classified
as Tier 1 variants if they had a CADD phred score  20. Furthermore, the variants were required to
be reported to be pathogenic or likely pathogenic by the ClinVar database or alternatively known
to aect a protein domain reported in Uniprot (e.g., occurring before or within a protein domain).
All nonsynonymous single nucleotide variants (missense variants) reported to be pathogenic or likely
pathogenic by ClinVar or had a CADD phred score  20 and REVEL score  0.75 were classified as
Tier 2 variants. The same prioritization criteria were applied to both case cohorts. The full workflow
including details of the sequencing data analysis is illustrated in Figure 1.
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Figure 1. Flow chart describing processing of whole exome sequencing, quality control, variant calling 
and annotation, and variant prioritizing. PRCA: prostate cancer; ClinVar: database of reported 
associations of variants to clinical phenotypes; CADD: combined annotation dependent depletion; 
Revel: rare exome variant ensemble learner. 
Figure 1. Flow chart describing processing of whole exome sequencing, quality control, variant
calling and annotation, and variant prioritizing. PRCA: prostate cancer; ClinVar: database of reported
associations of variants to clinical phenotypes; CADD: combined annotation dependent depletion;
Revel: rare exome variant ensemble learner.
2.5. Population Frequencies
To explore the expected population allele frequencies of pathogenic variants in the discovered
DNA repair genes, we extracted data from two subsets of the Exome Aggregation Consortium (ExAC)
browser [27], one set comprising 6192 Swedish population controls and one set comprising 3307
Finnish individuals unselected for cancer history. Full details of the data processing, variant calling
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and resources have been described previously [27]. Variant prioritization among these population
controls was performed by the same filtering algorithm as described above for the PrCa cases.
2.6. Statistical Analysis
Baseline characteristics were described using the median (interquartile range [IQR]) for continuous
variables and absolute and relative frequencies for categorical variables. The frequency of potentially
damaging DNA repair gene mutation carriers among the lethal PrCa patients was compared to the
frequency in unselected PrCa patients and the two control populations with the use of a two-sided
Fisher’s exact test. For the control populations, the frequency of mutation carriers in a specific gene
was calculated on the basis of the total number of persons for whom sequence coverage was adequate
for the given allele, under the assumption that each individual carried at most one deleterious mutation
in the explored gene. This assumption may have introduced a slight overestimation in the carrier
frequency in the control populations. In all analyses, Tier 1 and Tier 2 mutations were assessed
separately. No adjustment was made for multiple testing, and p values less than 0.05 were considered
to indicate statistical significance.
3. Results
We performed a comprehensive genetic assessment of DNA repair genes in 122 PrCa cases selected
for very aggressive disease and 70 PrCa cases unselected for disease aggressiveness. After exclusion of
10 samples due to insucient sequencing coverage, 122 lethal cases and 60 unselected cases remained
for analysis (Figure 1)—see Table 1 for the clinical characteristics of case cohorts.
Table 1. Clinical characteristics of patients.
Lethal PrCa
(n = 122)
Unselected
PrCa (n = 60)
Age at diagnosis, median (IQR) 57.0 (55.1–58.2) 66.5 (57.8–73.8)
Diagnostic PSA level (ng/mL), median (IQR) 56.2 (17.9–247.2) 10.8 (7.0–18.8)
Clinical T-stage, n (%)
TX 2 (1.8) 0 (0.0)
T1 8 (7.3) 20 (38.5)
T2 18 (16.4) 15 (28.8)
T3 61 (55.5) 15 (28.8)
T4 21 (19.1) 2 (3.8)
NA 12 8
Clinical N-stage, n (%)
NX 86 (78.2) 52 (100.0)
N0 9 (8.2) 0 (0.0)
N1 15 (13.6) 0 (0.0)
NA 12 8
Clinical M-stage, n (%)
MX 11 (10.0) 14 (26.9)
M0 45 (40.9) 32 (61.5)
M1 54 (49.1) 6 (11.5)
NA 12 8
Gleason score, n (%)
2–6 11 (10.5) 16 (47.1)
7 36 (34.3) 7 (20.6)
8–10 58 (55.2) 11 (32.4)
NA 17 26
Death due to PrCa, n (%) 122 (100.0) 15 (25.0)
Age at death, median (IQR) 60.0 (57.9–62.9) 79.5 (69.5–84.5)
PrCa: prostate cancer; PSA: prostate-specific antigen; NA: not available.
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In total, 22,850,167 variants were discovered and variant prioritization yielded 31 potentially
damaging variants distributed across 17 DNA repair genes among the cases (Table 2).
Table 2. Potentially damaging mutations identified in men with lethal prostate cancer.
Gene RSID Type Ref Alt ProteinChange ClinVar CADD/REVEL MAF Tier
ATM rs758081262 stopgain C T Q852X 5 35/- 2.5  10 5 1
ATM rs761486324 frameshiftins - TG H1082fs - -/- - 1
ATM rs767099464 frameshiftdel C - H1083fs - -/- - 1
ATM rs769142993 missense G C A2524P 4 31/0.89 2.5  10 5 2
ATM - frameshiftdel AGTAG - S2611fs - -/- - 1
ATM rs753961188 frameshiftins - T L2885fs 5,4 -/- 4.2  10
 5 1
ATM rs376676328 missense A G R2912G 3 29/0.88 3.0  10 4 2
BRCA1 rs41293459 missense C T R1699Q 5,4,3 35/0.79 2.5  10 5 2
CHEK2 rs555607708 frameshiftdel G - T367fs 5 -/- 1.8  10
 3 1
CHEK2 rs137853007 missense G A R145W 5,4 33/0.81 3.3  10 5 2
CHEK2 rs730881700 frameshiftins - T E457fs 5,4 -/- 5.0  10
 5 1
CHEK2 rs28909982 missense T C R117G 5,4 27/0.93 1.0  10 4 2
ERCC3 rs753182861 frameshiftdel T - Q586fs - -/- 2.0  10 4 1
ERCC3 rs145267069 missense A G F297S - 30/0.82 2.5  10 5 2
FAN1 rs778927800 missense G A R749Q - 34/0.89 8.3  10 6 2
FANCM rs147021911 stopgain C T Q1701X 4 35/0.12 1.3  10 3 1
HLTF rs184046773 missense C T G1886A - 33/0.81 2.0  10 4 2
MRE11A rs372000848 missense G A R305W 4,3 33/0.85 5.0  10 5 2
MUTYH rs34126013 missense G A R238W 5,4 33/0.79 9.2  10 5 2
NEIL1 rs5745906 missense G A G169D - 27/0.86 1.3  10 3 2
NTHL1 rs150766139 stopgain G A Q90X 5,3 35/- 1.5  10 3 1
POLG rs761584617 missense G A A1115V - 23/0.80 2.5  10 5 2
POLG rs113994097 missense C G W748S 5,3 33/0.91 8.0  10 4 2
POLG rs113994096 missense G A P587L 5,3 28/0.80 1.7  10 3 2
POLG rs121918052 missense C G Q497H 5,3 26/0.71 2.0  10 4 2
POLL rs139871590 missense C T G356S - 34/0.83 1.0  10 3 2
RAD18 rs138830303 stopgain T A K197X - 36/- 1.0  10 4 1
RECQL rs149937760 missense C T C414Y - 33/0.84 2.0  10 4 2
RECQL5 rs768705080 missense T G Y362S - 32/0.76 8.2  10 6 2
TP53 rs876660754 missense C T V173M 5,4 28/0.89 - 2
TP53 rs779000871 missense G A T170M 3 24/0.87 8.2  10 5 2
Note: ClinVar clinical significance score defines as: 5 = pathogenic, 4 = likely pathogenic, 3 = uncertain significance.
Minor allele frequency of variants derived from the Exome Aggregation Consortium. Ref: reference allele;
Alt: alternative allele; ClinVar: database of reported associations of variants to clinical phenotypes; CADD: combined
annotation dependent depletion; REVEL: rare exome variant ensemble learner; MAF: minor allele frequency;
ins: insertion; del: deletion.
Screening of those 17 genes among the population controls revealed 157 potentially damaging
variants (Supplementary Table S1) of which 137 were only discovered in the control populations, giving
a total of 168 potentially damaging variants. In total, 79 of these variants were known to be pathogenic
or likely pathogenic according to ClinVar, while the remaining variants were considered potentially
damaging due to their truncating eects on protein domains or by having a REVEL score  0.75 and a
CADD score  20. Of the 168 potentially damaging variants, 47 were classified as Tier 1 variants and
121 as Tier 2 variants. In total, 21 of the 47 Tier 1 variants were stopgain, 16 were frameshift indels,
and 10 were splicing site altering variants.
In exploring the final 168 variants among the 122 lethal cases, 15 men (12.3%) carried at least one
potentially damaging Tier 1 germline mutation in a DNA repair gene (one man carried two dierent
Tier 1 mutations in the ATM gene), which was significantly higher than that observed in unselected
cases (0%, p = 0.003, Table 3).
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Table 3. Carrier rates of potentially damaging mutations, stratified by Tier 1 and Tier 2 classification,
in men with lethal prostate cancer, unselected prostate cancer, and population controls.
Lethal PrCa
(n = 122)
Unselected
PrCa (n = 60)
p
Value
Finnish
Controls
(n = 3307)
p
Value
Swedish
Controls
(n = 6192)
p
Value
Tier 1
ERCC3, n (%) 1 (0.82) 0 1.000 0 0.036 3 (0.05) 0.075
RAD18, n (%) 1 (0.82) 0 1.000 0 0.036 0 0.019
ATM, n (%) 4 (3.28) 0 0.304 4 (0.12) <0.001 10 (0.16) <0.001
FANCM, n (%) 2 (1.64) 0 1.000 89 (2.69) 0.772 44 (0.71) 0.223
NTHL1, n (%) 2 (1.64) 0 1.000 24 (0.73) 0.236 39 (0.63) 0.187
CHEK2, n (%) 5 (4.10) 0 0.173 60 (1.81) 0.080 5 (0.08) <0.001
All, n (%) 15 (12.30) 0 0.003 177 (5.35) 0.004 101 (1.63) <0.001
Tier 2
MUTYH, n (%) 0 1 (1.67) 0.330 34 (1.03) 0.633 75 (1.21) 0.406
ERCC3, n (%) 1 (0.82) 1 (1.67) 0.552 5 (0.15) 0.195 4 (0.06) 0.093
HLTF, n (%) 1 (0.82) 0 1.000 20 (0.60) 0.534 9 (0.15) 0.177
POLL, n (%) 1 (0.82) 0 1.000 15 (0.45) 0.441 28 (0.45) 0.433
MRE11A, n (%) 1 (0.82) 0 1.000 0 0.036 0 0.019
ATM, n (%) 2 (1.64) 0 1.000 13 (0.39) 0.098 28 (0.45) 0.114
RECQL, n (%) 1 (0.82) 0 1.000 0 0.036 13 (0.21) 0.239
FAN1, n (%) 1 (0.82) 0 1.000 2 (0.06) 0.103 16 (0.26) 0.283
NEIL1, n (%) 1 (0.82) 0 1.000 3 (0.09) 0.135 16 (0.26) 0.283
POLG, n (%) 5 (4.10) 0 0.173 197 (5.96) 0.555 190 (3.07) 0.429
TP53, n (%) 2 (1.64) 0 1.000 3 (0.09) 0.012 7 (0.11) 0.012
BRCA1, n (%) 1 (0.82) 0 1.000 2 (0.06) 0.103 5 (0.08) 0.111
RECQL5, n (%) 1 (0.82) 0 1.000 3 (0.09) 0.135 1 (0.02) 0.038
CHEK2, n (%) 1 (0.82) 1 (1.67) 0.552 2 (0.06) 0.103 28 (0.45) 0.433
All, n (%) 16 (13.11) 3 (5.00) 0.123 299 (9.04) 0.148 420 (6.78) 0.011
PrCa: prostate cancer. P value: the frequency of potentially damaging DNA repair gene mutation carriers among
the lethal PrCa patients was compared to the frequency in unselected PrCa patients and the two control populations
with the use of a two-sided Fisher’s exact test.
No significant dierence in the Tier 1 mutation carrier rate was observed between Swedish (13.3%)
and Finnish (10.6%, p = 0.781) lethal cases. The two most frequently mutated genes were CHEK2 (4.1%)
and ATM (3.3%, Table 3, Figure 2). The observed carrier rate of Tier 1 mutations was significantly
higher in the lethal cases compared to the prevalence in the Swedish (1.6%, p < 0.001) and the Finnish
(5.4%, p = 0.040) population controls.
The observed carrier rate of potentially damaging Tier 2 germline mutations was higher in the
lethal cases (13.1%) compared to that of the unselected cases (5.0%); however, the dierence was not
statistically significant (p = 0.123, Table 3). Compared to Swedish controls (6.8%, p = 0.011), a higher
mutation rate was observed among the lethal cases; however, there was no statistically significant
dierence in the carrier rate of Tier 2 mutations between the lethal cases and the Finnish population
controls (9.0%, p = 0.148). No significant dierence in the Tier 2 mutation carrier rate was observed
between Swedish and Finnish lethal cases (p = 0.102).
No potentially damaging variants, neither Tier 1 nor Tier 2, were observed in the BRCA2 gene in
any of the PrCa cases. In the population controls, we observed a carrier rate of Tier 1 BRCA2 mutations
of 0.68% and 0.64% in Sweden and Finland, respectively.
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Figure 2. Potentially damaging variants found in the CHEK2 and ATM genes. Locations of variants are
shown as lollipop structures. The variants found in the Finnish/Swedish lethal or unselected cases
are indicated by circles, and variants found in selected previous studies [7,11,18,28] are indicated by
triangles. The variant type is indicated by the color.
4. Discussion
In this study, we characterized the germline variants occurring in the DNA repair pathway from
122 lethal and 60 unselected PrCa patients. In total, 16 potentially damaging protein truncating variants
(Tier 1) were identified in 15 men (12.3%) among the lethal cases significantly exceeding the carrier
rate of 0% in the unselected cases as well as the population prevalence of 1.6% and 5.4% in Swedish
and Finnish population controls. In contrast, the frequency of potentially damaging nonsynonymous
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single nucleotide variants (Tier 2) showed similar frequencies among lethal cases, unselected cases and
population controls.
Previous studies focusing on aggressive and metastatic PrCa cases have found higher frequencies
of deleterious germline variants in BRCA2 than in any other DNA repair gene and thus considered it
to be the major contributor among DNA repair genes to the aggressive phenotype [7,11,29]. However,
we observed a frequency of zero pathogenic BRCA2 variants in our lethal cases, suggesting that BRCA2
does not play a major role in aggressive and lethal PrCa in the Swedish and Finnish populations.
This agrees with earlier studies in which BRCA1 and BRCA2 were not found to have a significant
contribution to PrCa susceptibility or aggressiveness in Finland or Sweden [30,31]. In a recent study by
Mayrhofer and coworkers, sequencing of 217 metastatic PrCa cases from Sweden revealed only two
pathogenic BRCA2 mutation carriers (0.93% carrier rate, [31]). Assuming the same carrier rate among
our lethal cases, we would expect to find, on average, 1.1 carriers of BRCA2 mutations in our study,
and our null finding is therefore not surprising. In general, the frequencies of established prostate
cancer susceptibility variants deviate from population to population. One such case is the known
cancer susceptibility variant G84E in HOXB13, which has been shown to have a mutation frequency
approximately three-fold higher in Sweden and Finland compared to the mutation frequency in North
America [32–34].
ATM and its role in pancreatic cancer was recently reviewed [35] and germline mutations in
ATM have been associated with predisposition for several cancer forms [36] including PrCa [3].
Several studies have particularly reported potentially damaging variants in ATM in aggressive PrCa
cases [7,9,29,31]. We also found high frequencies of potentially damaging variants in our lethal cohort
(3.28% and 1.64% for Tier 1 and 2 variants, respectively), while in the unselected cases, the frequencies
of these variants were found to be very low, similar to those of the population controls. These data
support the evidence that deleterious variants in ATM are associated with the lethal phenotype of the
disease. ATM is known to have a predominant role in the DNA damage response, but it also plays a
role in maintaining the overall functionality of the cell [37]. ATM mutations that cause its inactivation
or deficiency have shown a variety of pathological manifestations, including oxidative stress, metabolic
syndrome, mitochondrial dysfunction and neurodegeneration. Recently ATM deficiency was shown to
promote the progression of castration-resistant PrCa by enhancing the Warburg eect, suggesting that
ATM mutation contributes through a metabolic—in addition to DNA repair—mechanism [38].
CHEK2 variants have been associated with PrCa predisposition in several studies [9,10], and we
found that this gene was the most frequently mutated Tier 1 gene in our study (4.1%). In a recent
study of 217 metastatic PrCa patients from Sweden [31], CHEK2 was also the most frequently mutated
DNA repair gene (3.8%), highlighting the importance of CHEK2 mutations for aggressive PrCa in the
Nordic population. Of note, in both the present study and the study by Mayrhofer and coworkers [31],
c.1100delC was the most commonly observed mutation in CHEK2 (3.2% and 1.9%, respectively).
Wu and coworkers also assessed the frequencies of potentially damaging CHEK2 variants in lethal
cases and in cases with localized low-risk PrCa from the US [39]. Overall, no association was found
between CHEK2 mutation status and lethal disease, but one variant, c.1100delC, was found to have a
significantly higher frequency in the lethal cases (1.3%) compared to that of the low-risk PrCa patients
(0.2%, p = 0.004), supporting the importance of this mutation for lethal PrCa. The c.1100delC has
been shown to trigger nonsense-mediated mRNA decay, and subsequent protein analyses suggested
that the truncated protein is likely highly unstable [40]. No mechanistic data are available for PrCa,
but patients with CHEK2 mutations are among those showing a high response rate to treatment with the
poly-ADP ribose polymerase inhibitor Olaparib when cancers were no longer responding to standard
treatments [41].
Of note, only heterozygous carriers of protein-truncating variants were observed in our study
conforming to the classical two-hit model for tumor suppressor genes [42,43]. No novel candidate
genes within the DNA repair pathway were found in our study. The lack of novel findings is not
surprising considering the limited sample size of the study. Moreover, we applied a relatively strict
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approach for prioritizing variants, which may have led us to underestimate the role of some genes or
even to completely miss potential candidate genes.
We pooled Finnish and Swedish lethal cases to improve the statistical power of the association
analysis. No adjustment for possible confounding, for example by population stratification, PSA
screening history or family history of PrCa, was performed. Population stratification is always of
importance in genetic association studies. However, genotypes from genome-wide single nucleotide
polymorphisms were not available for all cases and we were therefore not able to adjust for possible
population stratification through principal components in the current study. PSA screening is known to
decrease PrCa-specific mortality [44,45] and it is possible that screening history may have confounded
our analysis. However, for this to be the case PSA screening history must be associated with carrying
pathogenic mutations in DNA repair genes which we find unlikely. Finally, Pritchard and coworkers [11]
reported that deleterious mutation frequencies of DNA repair genes did not dier according to whether
a family history of PrCa was present among 692 men with metastatic PrCa. Therefore, we argue that
confounding by family history is of limited concern in our study.
5. Conclusions
In conclusion, germline variants in DNA repair genes have been shown to be associated with the
aggressive form of PrCa—a finding that is supported by our study. Unlike previous studies, we did
not observe high numbers of potentially damaging germline variants in BRCA2. Instead, mutations in
ATM and CHEK2 were found to be most frequent among the lethal cases, highlighting the importance
of the population-specific assessment of the variants contributing to the aggressiveness of PrCa.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/3/314/s1,
Table S1: Potentially damaging variants discovered in control populations.
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